Export

Neostigmine
Essential medicine status
General description
Neostigmine is a reversible anticholinesterase agent indicated as a treatment for myasthenia gravis; and for use in the reversal of non-depolarizing muscle relaxants administered during surgery.
INN
Neostigmine bromide
Medicine type
Chemical agent
EML status history
First added in 1977 (TRS 615) for Anticholinesterase reversible
Added in 1977 (TRS 615) for Myasthenia gravis
Therapeutic equivalent for
Wikipedia
DrugBank
Recommendations
Section
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
  • Oral > Solid: 15 mg (neostigmine bromide)
  • Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)